Shares of Integra lifesciences (NASDAQ:IART) have been assigned an average recommendation of “Hold” from the eighteen research firms that are covering the firm, MarketBeat.com reports. Eleven investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $59.42.
A number of brokerages have weighed in on IART. JPMorgan Chase raised their price objective on Integra lifesciences from $50.00 to $55.00 and gave the company a “neutral” rating in a report on Wednesday, April 11th. BidaskClub upgraded Integra lifesciences from a “hold” rating to a “buy” rating in a report on Friday, March 23rd. Morgan Stanley raised their price objective on Integra lifesciences from $53.00 to $58.00 and gave the company an “equal weight” rating in a report on Thursday, April 26th. Oppenheimer restated a “buy” rating on shares of Integra lifesciences in a report on Thursday, March 22nd. Finally, Citigroup raised their price objective on Integra lifesciences from $60.00 to $70.00 and gave the company an “outperform” rating in a report on Thursday, April 26th.
Shares of Integra lifesciences traded up $0.37, reaching $64.79, during midday trading on Friday, MarketBeat.com reports. 633,909 shares of the company’s stock traded hands, compared to its average volume of 585,100. Integra lifesciences has a 1 year low of $41.51 and a 1 year high of $65.28. The firm has a market capitalization of $5.04 billion, a price-to-earnings ratio of 33.40, a price-to-earnings-growth ratio of 1.91 and a beta of 0.66. The company has a debt-to-equity ratio of 1.77, a current ratio of 2.53 and a quick ratio of 1.66.
Integra lifesciences (NASDAQ:IART) last announced its earnings results on Wednesday, April 25th. The life sciences company reported $0.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.49 by $0.09. Integra lifesciences had a return on equity of 17.90% and a net margin of 5.39%. The firm had revenue of $357.10 million for the quarter, compared to analyst estimates of $349.15 million. During the same quarter last year, the firm posted $0.39 EPS. The business’s revenue was up 38.1% on a year-over-year basis. sell-side analysts expect that Integra lifesciences will post 2.41 earnings per share for the current year.
In other Integra lifesciences news, major shareholder Richard E. Caruso sold 32,880 shares of the firm’s stock in a transaction on Thursday, March 8th. The stock was sold at an average price of $53.68, for a total value of $1,764,998.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Keith Bradley sold 15,658 shares of the firm’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $55.00, for a total value of $861,190.00. Following the completion of the sale, the director now directly owns 37,074 shares of the company’s stock, valued at $2,039,070. The disclosure for this sale can be found here. Insiders sold a total of 80,765 shares of company stock valued at $4,376,248 over the last ninety days. Corporate insiders own 5.10% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the business. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Integra lifesciences by 38.3% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,806 shares of the life sciences company’s stock worth $182,000 after acquiring an additional 1,054 shares during the last quarter. Stanley Laman Group Ltd. acquired a new stake in shares of Integra lifesciences during the 1st quarter worth about $221,000. Zions Bancorporation acquired a new stake in shares of Integra lifesciences during the 1st quarter worth about $235,000. Hsbc Holdings PLC acquired a new stake in shares of Integra lifesciences during the 1st quarter worth about $235,000. Finally, Quantitative Systematic Strategies LLC acquired a new stake in shares of Integra lifesciences during the 1st quarter worth about $270,000. 90.86% of the stock is owned by institutional investors and hedge funds.
About Integra lifesciences
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
Receive News & Ratings for Integra lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.